640 related articles for article (PubMed ID: 32227567)
21. Tezacaftor for the treatment of cystic fibrosis.
Sala MA; Jain M
Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878
[TBL] [Abstract][Full Text] [Related]
22. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.
Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C
Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799
[TBL] [Abstract][Full Text] [Related]
23. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
24. Tezacaftor and ivacaftor for the treatment of cystic fibrosis.
Paterson SL; Barry PJ; Horsley AR
Expert Rev Respir Med; 2020 Jan; 14(1):15-30. PubMed ID: 31626570
[No Abstract] [Full Text] [Related]
25. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis.
Vaidyanathan S; Trumbull AM; Bar L; Rao M; Yu Y; Sellers ZM
Genet Med; 2022 Oct; 24(10):2180-2186. PubMed ID: 35857025
[TBL] [Abstract][Full Text] [Related]
26. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
27. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy.
Fortner CN; Seguin JM; Kay DM
J Cyst Fibros; 2021 Sep; 20(5):835-836. PubMed ID: 33846105
[No Abstract] [Full Text] [Related]
28. L1077P CFTR pathogenic variant function rescue by Elexacaftor-Tezacaftor-Ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients.
Lo Cicero S; Castelli G; Blaconà G; Bruno SM; Sette G; Pigliucci R; Villella VR; Esposito S; Zollo I; Spadaro F; Maria R; Biffoni M; Cimino G; Amato F; Lucarelli M; Eramo A
Respir Res; 2023 Sep; 24(1):217. PubMed ID: 37674160
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
30. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
31. CFTR Modulators Rescue the Activity of CFTR in Colonoids Expressing the Complex Allele p.[R74W;V201M;D1270N]/dele22_24.
Kleinfelder K; Somenza E; Farinazzo A; Conti J; Lotti V; Latorre RV; Rodella L; Massella A; Tomba F; Bertini M; Sorio C; Melotti P
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982273
[TBL] [Abstract][Full Text] [Related]
32. Hispanic Infants with cystic fibrosis show low CFTR mutation detection rates in the Illinois newborn screening program.
Watts KD; Layne B; Harris A; McColley SA
J Genet Couns; 2012 Oct; 21(5):671-5. PubMed ID: 22311127
[TBL] [Abstract][Full Text] [Related]
33. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis.
Cheng PC; Alexiou S; Rubenstein RC
Expert Rev Respir Med; 2019 May; 13(5):417-423. PubMed ID: 30929526
[TBL] [Abstract][Full Text] [Related]
35. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Complex p.[Leu467Phe;Phe508del] CFTR Allele in the Intestinal Organoids Model: Implications for Therapy.
Kondratyeva E; Efremova A; Melyanovskaya Y; Voronkova A; Polyakov A; Bulatenko N; Adyan T; Sherman V; Kovalskaia V; Petrova N; Starinova M; Bukharova T; Kutsev S; Goldshtein D
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142302
[TBL] [Abstract][Full Text] [Related]
37. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
[TBL] [Abstract][Full Text] [Related]
38. Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators.
Terlizzi V; Pesce E; Capurro V; Tomati V; Lena M; Pastorino C; Bocciardi R; Zara F; Centrone C; Taccetti G; Castellani C; Pedemonte N
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047546
[TBL] [Abstract][Full Text] [Related]
39. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
40. Reclassifying inconclusive diagnosis after newborn screening for cystic fibrosis. Moving forward.
Hatton A; Bergougnoux A; Zybert K; Chevalier B; Mesbahi M; Altéri JP; Walicka-Serzysko K; Postek M; Taulan-Cadars M; Edelman A; Hinzpeter A; Claustres M; Girodon E; Raynal C; Sermet-Gaudelus I; Sands D
J Cyst Fibros; 2022 May; 21(3):448-455. PubMed ID: 34949556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]